Patients with cancer must also have full staging investigations to rule out other sites of disease progression and cannot actively be receiving chemotherapy or radiotherapy. If no exclusion exists, the patient will be randomized to HBO2T or standard of care treatment. HBO2T will consist of 100% oxygen at 2.4 ATA for 90 min daily, at least 5 days per week, for 30 treatments. The selection of this regimen is based both on the safety and efficacy observed in other FDA approved

uses Navitoclax including radiation necrosis of non-neural soft tissues. All patients will be monitored throughout their treatment period for progression of symptoms and their steroid requirement. They will also receive repeat MRI scans of the head after completion of the treatment protocol (30 days) and again and at 90 days following completion of treatment protocol. Formal neuropsychological

evaluation will be done at enrollment and repeated at 90 days post-treatment. Quality of Talazoparib order life measures, such as the EORTC QLQ-C30 and BN 20 will be administered at enrollment and 90 days as well [70] and [71]. Primary outcomes will be progression, stabilization or resolution of symptoms measured by the neurologist, as well as progression, stabilization, or resolution of the lesions on MRI imaging where RECIST (response evaluation criteria in solid tumors) criteria will be applied [72]. RAS p21 protein activator 1 Secondary outcomes will include change in neuropsychological measures and, the steroid requirement as compared to control. All measures will be assessed at 90 days post-treatment. To determine whether use of HBO2T will relieve headache pain in status migrainosus. Migraine is a common disorder. One-year prevalence is approximately

18% and 7% for American woman and men, respectively [73]. Status Migrainosus, as defined by The International Headache Society’s International Classification of Headache Disorders, 2nd edition [74], is a migraine attack lasting more than 72 h that is typical of previous attacks except in duration, and that cannot be attributed to another disorder. While usually felt to be a rare phenomenon, in a recent retrospective study, 20% of migraineurs reported episodes which met these criteria [75]. Current knowledge suggests that primary neuronal dysfunction leads to intracranial and extracranial changes that account for migraine [76]. Those prone to migraine have a genetic migrainous threshold that leaves them susceptible to acute attacks, dependent on the balance of excitation and inhibition at various levels of the nervous system. Genetic and environmental factors both play a role [77]. Nevertheless, it is believed that vasodilatation still plays an integral part in the severe throbbing pain characteristic of migraine, likely secondary to instability in the central neurovascular control mechanism [78].